ASUNCTIS

ASUNCTIS IS AN OPEN-LABEL, RANDOMIZED, PHASE II STUDY WITH THE MAIN OBJECTIVE TO INVESTIGATE THE EFFECTIVENESS AND SAFETY OF AN INVESTIGATIONAL DRUG (APG101; INTERNATIONAL NONPROPRIETARY NAME: ASUNERCEPT) IN PATIENTS WITH SEVERE COVID-19 DISEASE. THE STUDY AIMS TO DECREASE OVERALL AND SARS-COV-2 ASSOCIATED PNEUMONIA MORTALITY IN PATIENTS WITH COVID-19 AS WELL AS TO DECREASE THE PERCENTAGE OF PATIENTS ADMITTED TO INTENSIVE CARE UNIT (ICU), DECREASE THE NEED TO SUPPLY OXYGEN TO PATIENTS, REDUCE THE NUMBER OF DAYS PATIENTS ARE HOSPITALIZED IN ICU AND/OR ON THE WARD, DECREASE THE NUMBER OF DAYS REQUIRED TO OBTAIN A NEGATIVE RESULT IN THE PCR (POLYMERASE CHAIN REACTION, A LABORATORY TECHNIQUE THAT ALLOWS THE AMPLIFICATION OF SMALL FRAGMENTS OF DNA TO DETECT THE PRESENCE OF THE VIRUS) TEST FOR COVID-19 AND DECREASE THE LEVELS OF MARKERS THAT INDICATE PNEUMONIA.